Search Within

Gregory J Riely

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (57)
  2. Meeting Abstract (27)
  3. Conference Paper (1)
Groups
  1. Department of Medicine (85)
  2. Sloan Kettering Institute Postdocs (85)
  3. Solid Tumor Oncology Division (85)
  4. Thoracic Oncology (85)
  5. GSK Faculty (80)
  6. Department of Pathology and Laboratory Medicine (76)

More Groups

People
  1. Marc Ladanyi (60)
  2. Mark Kris (45)
  3. Charles Rudin (40)
  4. Helena Yu (30)
  5. Alexander Drilon (29)
  6. Maria Arcila (28)

More People

Years
  1. 2024 (6)
  2. 2023 (14)
  3. 2022 (8)
  4. 2021 (5)
  5. 2020 (5)
  6. 2019 (13)

More Years

Publications
  1. Journal of Thoracic Oncology (16)
  2. Journal of Clinical Oncology (15)
  3. Clinical Cancer Research (14)
  4. Annals of Oncology (5)
  5. JCO Precision Oncology (5)
  6. Cancer Discovery (4)

More Publications

Publishers
  1. American Association for Cancer Research (23)
  2. American Society of Clinical Oncology (20)
  3. Elsevier Inc. (16)
  4. Nature Publishing Group (8)
  5. Oxford University Press (6)
  6. Cell Press (2)

More Publishers

Results (85)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tissue-based molecular and histologic landscape of acquired resistance to osimertinib in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A.; Chan, J.; Rizvi, H.; Somwar, R.; Kubota, D.; Daneshbod, Y.; Chang, J.; Offin, M.; Arcila, M.; Pe'Er, D.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers
    Meeting Abstract

    Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Journal Article

    Hastings, K.; Yu, H. A.; Wei, W.; Sanchez-Vega, F.; DeVeaux, M.; Choi, J.; Rizvi, H.; Lisberg, A.; Truini, A.; Lydon, C. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A. J.; Chan, J. M.; Rizvi, H.; Rekhtman, N.; Daneshbod, Y.; Kubota, D.; Chang, J. C.; Arcila, M. E.; Ladanyi, M.; Somwar, R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
    Journal Article

    Offin, M.; Chan, J. M.; Tenet, M.; Rizvi, H. A.; Shen, R.; Riely, G. J.; Rekhtman, N.; Daneshbod, Y.; Quintanal-Villalonga, A.; Penson, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Immunophenotype and response to immunotherapy of RET-rearranged lung cancers
    Journal Article

    Offin, M.; Guo, R.; Wu, S. L.; Sabari, J.; Land, J. D.; Ni, A.; Montecalvo, J.; Halpenny, D. F.; Buie, L. W.; Pak, T.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Schoenfeld, A. J.; Plodkowski, A. J.; Odintsov, I.; Lu, D.; Lockwood, W. W.; Arcila, M. E.; Rudin, C. M.; Drilon, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: Results from the Actionable Genome Consortium
    Journal Article

    Li, B. T.; Janku, F.; Jung, B.; Hou, C.; Madwani, K.; Alden, R.; Razavi, P.; Reis-Filho, J. S.; Shen, R.; Isbell, J. M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers
    Journal Article

    Vojnic, M.; Kubota, D.; Kurzatkowski, C.; Offin, M.; Suzawa, K.; Benayed, R.; Schoenfeld, A. J.; Plodkowski, A. J.; Poirier, J. T.; Rudin, C. M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Exceptional responders with invasive mucinous adenocarcinomas: A phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
    Journal Article

    Drilon, A.; Schoenfeld, A. J.; Arbour, K. C.; Litvak, A.; Ni, A.; Montecalvo, J.; Yu, H. A.; Panora, E.; Ahn, L.; Kennedy, M.; more...
    Cold Spring Harbor Molecular Case Studies (2019)

    Fulltext@MSK | Save